Dataset Information


HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice.

ABSTRACT: BACKGROUND:Chronic hepatitis B virus (HBV) infection remains incurable. Although HBsAg-specific chimeric antigen receptor (HBsAg-CAR) T cells have been generated, they have not been tested in animal models with authentic HBV infection. METHODS:We generated a novel CAR targeting HBsAg and evaluated its ability to recognize HBV+ cell lines and HBsAg particles in vitro. In vivo, we tested whether human HBsAg-CAR T cells would have efficacy against HBV-infected hepatocytes in human liver chimeric mice. RESULTS:HBsAg-CAR T cells recognized HBV-positive cell lines and HBsAg particles in vitro as judged by cytokine production. However, HBsAg-CAR T cells did not kill HBV-positive cell lines in cytotoxicity assays. Adoptive transfer of HBsAg-CAR T cells into HBV-infected humanized mice resulted in accumulation within the liver and a significant decrease in plasma HBsAg and HBV-DNA levels compared with control mice. Notably, the fraction of HBV core-positive hepatocytes among total human hepatocytes was greatly reduced after HBsAg-CAR T cell treatment, pointing to noncytopathic viral clearance. In agreement, changes in surrogate human plasma albumin levels were not significantly different between treatment and control groups. CONCLUSIONS:HBsAg-CAR T cells have anti-HBV activity in an authentic preclinical HBV infection model. Our results warrant further preclinical exploration of HBsAg-CAR T cells as immunotherapy for HBV.


PROVIDER: S-EPMC6038120 | BioStudies | 2018-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5626922 | BioStudies
2006-03-28 | GSE4549 | GEO
2008-06-13 | E-GEOD-4549 | ArrayExpress
2019-01-01 | S-EPMC6520809 | BioStudies
2017-01-01 | S-EPMC5605403 | BioStudies
2017-01-01 | S-EPMC5571312 | BioStudies
2017-01-01 | S-EPMC5473824 | BioStudies
2018-01-01 | S-EPMC6127945 | BioStudies
2010-01-01 | S-EPMC2838095 | BioStudies
1000-01-01 | S-EPMC5913918 | BioStudies